| Followers | 236 |
| Posts | 15419 |
| Boards Moderated | 1 |
| Alias Born | 03/29/2014 |
Friday, October 24, 2014 6:15:37 PM
If I were Linda, and I had two companies I was invested in, that were linked at the hip, so to say, I'd try to look out for both of them.
Now, whatever the price is that NWBO (our company) is paying Cognate (more Linda's company, a private company), when the price is negotiated for the vaccine, it establishes what FMV is for this vaccine - as I don't know of any other company making vaccines like this at this time. And if I were Linda, I'd make sure the negotiated price worked out well for both of my companies.
Perhaps another company will come along and, after L is approved, and perhaps Direct is close to approval (or approved), will offer the product for less to NWBO. Perhaps Cognate will offer a significantly lower price for making the vaccine because the volume has increased, and NWBO will decline the offer because Cognate is now providing the product for a competitive price. But at this time, other than hiring a CFO to negotiate with Cognate (and Linda) for a FMP, we are stuck with this company that appears to be delivering the product in a manner that Germany and England find acceptable at this time. What more can be done?
Recent NWBO News
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 11/26/2025 05:15:34 AM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/31/2025 09:23:24 PM
FEATURED Cannabix Technologies Announces Commercial Launch of Marijuana Breath Test (MBT) • Mar 16, 2026 8:37 AM
Record Gold Prices Reshape Economics of New Mine Development • SNWGF • Mar 16, 2026 10:46 AM
Exxe Group Advances Platform Strategy and Share Structure Reduction Following Strategic Meetings • AXXA • Mar 11, 2026 1:03 PM
DRCR Pushes Forward With Implementation of 2026 Business Plan • DRCR • Mar 11, 2026 12:26 PM
Record Gold Prices Reshape Opportunities for Emerging Producers • LFLR • Mar 11, 2026 9:00 AM
C2 Blockchain Reports 803 Million DOG (Bitcoin) Holdings Following Strategic Accumulation of Bitcoin-Native Digital Assets • CBLO • Mar 10, 2026 8:00 AM
